Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
1.
Braz. j. infect. dis ; 9(1)Feb. 2005. tab, graf
Article Dans Anglais | LILACS | ID: lil-404304

Résumé

This prospective study, involving 76 pregnant women infected with HIV, paired with their 79 exposed infants, was carried out between May 1996 and October 2001, at the Reference Department for Pregnant Women Infected with HIV in Campo Grande, Mato Grosso do Sul. The mean age of the pregnant women was 24 years; 88 percent (67/76) apparently were infected due to sexual practices; 88 percent (67/76) were housewives; 823 percent (63/76) graduated from junior high school; 14.5 percent (11/76) reported co-infection with Hepatitis C, 9.2 percent with Syphilis; 51 percent (39/76) learned the diagnosis during prenatal care; 67 percent (51/76) reported HIV clinical symptomatology and 9.2 percent (7/76) reported opportunistic infections. Elective cesareans were performed in 57 percent (43/76). The mean gestational age at delivery was 38 weeks and we found 12.5 percent (10/80) pronatis; 97 percent (74/76) had a ruptured membrane time after less than four hours and one child (1.3 percent) was nursed. ACTG 076 Protocol (AIDS Clinical Trial Group 076) was used in 80 percent (61/76) of the pregnant women, with 100 percent adherence; 62 percent (38/61) used zidovudine plus another antiretroviral in the gestation; 92 percent (73/79) of the infants used zidovudine after the birth and 19 percent (14/73) used zidovudine and lamivudine. The transmission rate in this study was 2.5 percent.


Sujets)
Adolescent , Adulte , Femelle , Humains , Nouveau-né , Grossesse , Agents antiVIH/usage thérapeutique , Infections à VIH/transmission , Transmission verticale de maladie infectieuse , Complications infectieuses de la grossesse , Brésil/épidémiologie , Études de cohortes , Test ELISA , Études de suivi , Infections à VIH/diagnostic , Infections à VIH/prévention et contrôle , Lamivudine/usage thérapeutique , Études prospectives , Facteurs de risque , Charge virale , Zidovudine/usage thérapeutique
SÉLECTION CITATIONS
Détails de la recherche